Examining reports and policies on cognitive enhancement: Approaches, rationale, and recommendations

Accountability in Research

Volumn 18, Issue 5, 2011, Pages 323-341

  Outram, Simon M ^a   Racine, Eric ^b,c,d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Biomedical enhancement; Enhancement technologies; Health policy; Psychotropic drugs

Indexed keywords

NOOTROPIC AGENT;

ARTICLE; AWARENESS; CLINICAL COMPETENCE; COGNITION; DRUG EFFECT; GOVERNMENT REGULATION; HEALTH; HEALTH CARE POLICY; HUMAN; PHYSICIAN; POLICY; PSYCHOLOGICAL ASPECT; RESEARCH ETHICS; SELF EVALUATION; UNITED STATES;

AWARENESS; CLINICAL COMPETENCE; COGNITION; ETHICS, RESEARCH; GOVERNMENT REGULATION; HEALTH POLICY; HUMANS; NOOTROPIC AGENTS; PHYSICIANS; PUBLIC POLICY; SELF-ASSESSMENT; UNITED STATES; WORLD HEALTH;

EID: 80052848194     PISSN: 08989621     EISSN: 15455815     Source Type: Journal    
DOI: 10.1080/08989621.2011.606734     Document Type: Article

References (60)

1. AAN. (2009). Responding to requests from adult patients for neuroenhancement. Neurology, 73 (17): 1406-1412. Available at: http://www.aan.com/go/about/position.Last accessed February 17, 2011.
2. Babcock, Q., and Byrne, T. (2000). Student perceptions of methylphenidate abuse at a public liberal arts college. Journal of American College Health, 49(3):143-145.
3. Barrett, S. P., Darredeau, C., Bordy, L. E., and Pihl, R. O. (2005). Characteristics of methylphenidate misuse in a university student sample. Canadian Journal of Psychiatry, 50(8):457-461.
4. Bell, E., Mathieu, G., and Racine, E. (2009). Preparing the ethical future of deep brain stimulation. Surgical Neurology, 72(6):577-586.
5. BMA. (2007). Boosting your brainpower: Ethical aspects of cognitive enhancement. Available at http://www.bma.org.uk/images/Boosting_brainpower_tcm41-147266.pdf. Last accessed February 24, 2011.
6. Bosk, C. L. (1999). Professional ethicist available: Logical, secular, friendly. Daedalus, 128(4):47-68.
7. Bostrom, N., and Sandberg, A. (2009). Cognitive enhancement: Methods, ethics, regulatory challenges. Science and Engineering Ethics, 15(3):311-341.
8. Boyatzis, R. E. (1998). Transforming Qualitative Information: Thematic Analysis and Code Development. Thousand Oaks, CA: Sage Publications.
9. Brown, N. (2003) Hope against hype-Accountability in biopasts, presents and futures. Science Studies, 16(2):3-21.
10. Cakic, V. (2009). Smart drugs for cognitive enhancement: Ethical and pragmatic considerations in the era of cosmetic neurology. Journal of Medical Ethics, 35(10):611-615.
11. CEST. (2009). Psychiatric Drugs and Expanded Uses: An Ethical Perspective. Available at: http://www.ethique.gouv.qc.ca/index.php?option=com_docman&Itemid=108. Last accessed February 24, 2011.
12. Chatterjee, A. (2006). The promise and predicament of cosmetic neurology. Journal of Medical Ethics, 32(2):110-113.
13. Churchill, L. R. (1999). Are we professionals? A critical look at the social role of bioethicists. Daedalus, 128(4):253-274.
14. De Vries, R. (2005). Framing neuroethics: A sociological assessment of the neuroethical imagination. American Journal of Bioethics, 5(2):25-27.
15. Elliott, R., Sahakian, B. J., Matthews, K., Bannerjea, A., Rimmer, J., and Robbins, T. W. (1997). Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology, 131(2):196-206.
16. Eriksson, S., Höglund, A. T., and Helgesson, G. (2008). Do ethical guidelines give guidance? A critical examination of eight ethics regulations. Cambridge Quarterly of Healthcare Ethics, 17(1):15-29.
17. Farah, M. J., Illes, J., Cook-Deegan, R., Gardner, H., Kandel, E., King, P., Parens, C., Sahakian, B., and Wolpe, P. R. (2004). Neurocognitive enhancement: What can we do and what should we do? Nature Reviews Neuroscience, 5(5):421-425.
18. Greely, H., Sahakian, B., Harris, J., Kessler, R. C., Gazzaniga, M., Campbell, P., and Farah, M. J. (2008). Towards responsible use of cognitive-enhancing drugs by the healthy. Nature, 456:702-705.
19. Guyer, R. L., and Moreno, J. D. (2004). Slouching toward policy: Lazy bioethics and the perils of science fiction. American Journal of Bioethics, 4(4):W14-17.
20. Hall, K. M., Irwin, M. M., Bowman, K. A., Frankenberger, W., and Jewett, D. C. (2005). Illicit use of prescribed stimulant medication among college students. Journal of American College Health, 53(4):167-174.
21. Hall, W. (2004). Feeling 'better than well'. EMBO Reports, 5(12):1105-1109.
22. Healy, D., and Cattell, D. (2003). Interface between authorship, industry and science in the domain of therapeutics. The British Journal of Psychiatry, 183:22-27.
23. Hedgecoe A. (2010). Bioethics and the reinforcement of socio-technical expectations. Social Studies of Science, 40(2):163-186.
24. Hedgecoe, A. M. (2004). Critical bioethics: Beyond the social science critique of applied ethics. Bioethics, 18(2):120-143.
25. Hedgecoe, A., and Martin, P. (2003). The drugs don't work: Expectations and the shaping of pharmacogenetics. Social Studies of Science, 33(3):327-364.
26. Hotze, T.D., Shah, K., Anderson, E.E., and Wynia, M.K. (2011) "Doctor, would you prescribe a pill to help me...?" A national survey of physicians on using medicine for human enhancement. American Journal of Bioethics, 11(1):3-13.
27. Irwin, A., and Wynne, B. (1996). Misunderstanding Science? The Public Reconstruction of Science and Technology. Cambridge; New York: Cambridge University Press.
28. Johnston, L. D., O'Malley, P. M., Bachman, J. G., and Schulenberg, J. E. (2010a). Monitoring the Future national survey results on drug use, 1975-2009. Volume I: Secondary school students. NIH Publication No. 10-7584).
29. Bethesda, M.D.: National Institute on Drug Abuse, 734 pp. Available at: http://www.monitoringthefuture.org/pubs.html#monographs. Last accessed February 15, 2011.
30. Johnston, L. D., O'Malley, P. M., Bachman, J. G., and Schulenberg, J. E. (2010b). Monitoring the Future national survey results on drug use, 1975-2009. Volume II: College students and adults ages 19-50. NIH Publication No. 10-7585). Bethesda, MD: National Institute on Drug Abuse, 305 pp. Available at: http://www.monitoringthefuture.org/pubs.html#monographs. Last accessed February 15, 2011.
31. Kass, L. R. (Spring 2003). Ageless bodies, happy souls: Biotechnology and the pursuit of perfection. The New Atlantis, 9-28.
32. Koelega, H. S. (1993). Stimulant drugs and vigilance performance: A review. Pharmacology, 111:1-16.
33. Kumar, R. (2008). Approved and investigational uses of modafinil: An evidence-based review. Drugs, 68(13):1803-1839.
34. Locke, S. (2002). The public understanding of science-A rhetorical invention. Science Technology and Human Values, 27:87-111.
35. Maher, B. (2008). Poll results: Look who's doping. Nature, 452(10):674-675.
36. Mehta, M. A., Owen, A. M., Sahakian, B. J., Mavaddat, N., Pickard, J. D., and Robbins, T. W. (2000). Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. Journal of Neuroscience, 20(6): 65RC. Available at: http://www.jneurosci.org/cgi/reprint/20004029v1. Last accessed February 24, 2011.
37. Minzenberg, M.J., and Carter, C.S. (2008).Modafinil: A review of neurochemical actions and effects on cognition. Neuropsychopharmacology, 33(7):1477-1502.
38. Nestadt, G., Di, C., Samuels, J. F., Bienvenu, O. J., Reti, I. M., Costa, P., Eaten, W. W., and Bandee-Roche, K. (2010). The stability of DSM personality disorders over twelve to eighteen years. Journal of Psychiatric Research, 44(1):1-7.
39. Nordmann, A. (2007). If and then: A critique of speculative nanoethics. Nanoethics, 1(1):31-46.
40. Oldani, M. (2009). Beyond the naive "no-see": Ethical prescribing and the drive forpharmaceutical transparency. PM&R, 1(1):82-86.
41. Oldani, M. J. (2004). Thick prescriptions: Toward an interpretation of pharmaceutical sales practices. Medical Anthropology Quarterly, 18(3):325-356.
42. Outram, S. M. (2010). The use of methylphenidate among students: The future of enhancement? Journal of Medical Ethics, 36(4):198-202.
43. Parens, E. (2005). Authenticity and ambivalence. Hastings Center Report, 35(3):34-41.
44. Racine, E., and Forlini, C. (2009). Expectations regarding cognitive enhancement create substantial challenges. Journal of Medical Ethics, 35(8):469-70.
45. Racine, E., and Forlini, C. (2010). Cognitive enhancement, lifestyle choice or misuse of prescription drugs? Neuroethics, 3(1):1-4.
46. Randall, D. C., Shneerson, J. M., and File, S. E. (2005). Cognitive effects of modafinil in student volunteers may depend on IQ. Pharmacology Biochemistry and Behavior, 82(1):133-139.
47. Repantis, D., Schlattmann, P., Laisney, O., and Heuser, I. (2010). Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacological Research, 62(3):187-206.
48. Rose, S. P. R. (2002). Science and society: 'Smart drugs': Do they work? Are they ethical? Will they be legal? Nature Reviews Neuroscience, 3(12):975-979.
49. Sahakian, B., and Morein-Zamir, S. (2007). Professor's little helper. Nature, 450(7173):1157-1159.
50. Salter, B., and Salter, C. (2007). Bioethics and the global moral economy: The cultural politics of human embryonic stem cell science. Science, Technology and Human Values, 32(5):554-581.
51. Sandel, M. J. (2004). T. The case against perfection. Atlantic Monthly. 293(3):50-62.
52. Savulescu, J. (2006). Justice, fairness, and enhancement. Annals of the New York Academy of Sciences, 1093:321-338.
53. Savulescu, J., Foddy, B., and Clayton, M. (2004). Why we should allow performance enhancing drugs in sport. British Journal of Sports Medicine, 38(6):666-670.
54. Schermer, M., Bolt, I., de Jong, R., and Olivier, B. (2009). The future of psychopharmacological enhancements: Expectations and Policies. Neuroethics, 2(2):75-87.
55. Sismondo, S. (2008). How pharmaceutical industry funding affects trial outcomes: Causal structures and responses. Social Science and Medicine, 66(9):1909-1914.
56. Stein, D.J., Phillips, K.A., Bolton, D., Fulford, K.W.M, Sadler, J.Z., and Kendler, K.S. (2010). What is a mental/psychiatric disorder? From DSM-IV to DSM-V. Psychological Medicine, 40:1759-1765.
57. Teter, C. J., McCabe, S. E., Cranford, J. A., Boyd, C. J., and Guthrie, S. K. (2005). Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. Journal of American College Health, 53(6):253-262.
58. Turner, D. C., Robbins, T. W., Clark, L., Aron, A. R., Dowson, J., and Sahakian, B. J. (2003). Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology, 165(3):260-269.
59. Turner, L. (2009). Bioethics and social studies of medicine: Overlapping concerns. Cambridge Quarterly of Healthcare Ethics, 18(1):36-42.
60. White, B. P., Becker-Blease, K., and Grace-Bishop, K. (2006). Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. Journal of American College Health, 54(5):261-268.